These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 19910392)

  • 21. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
    Voutsadakis IA; Cairoli A
    Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.
    Defina M; Rondoni M; Gozzetti A; Aprile L; Chitarrelli I; Fabbri A; Lauria F; Bocchia M
    Br J Haematol; 2010 Feb; 148(3):483-4. PubMed ID: 19874309
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of lenalidomide in multiple myeloma.
    Schey S; Higginson I
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):229-38. PubMed ID: 20545587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
    Shortt J; Hsu AK; Johnstone RW
    Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
    Abouyahya I; Alhan C; Westers TM; te Boekhorst PA; Kappers-Klunne MC; Coenen JL; Heyning FH; Huls GA; de Wolf JT; Imholz AL; Koene HR; Veth G; de Kruijf EJ; Muus P; Planken EV; Segeren CM; Vasmel WL; van der Velden AM; Velders GA; Koedam J; Ossenkoppele GJ; van de Loosdrecht AA
    Leuk Lymphoma; 2013 Apr; 54(4):874-7. PubMed ID: 22971215
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
    Ortega J; List A
    Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular mechanisms of lenalidomide for the treatment of myelodysplastic syndromes].
    Katayama Y
    Rinsho Ketsueki; 2011 Jul; 52(7):447-51. PubMed ID: 21821975
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
    Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
    Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
    Goss TF; Szende A; Schaefer C; Totten PJ; Knight R; Jädersten M; Hellström-Lindberg E; List AF
    Cancer Control; 2006 Dec; 13 Suppl():17-25. PubMed ID: 17242663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide in del 5q MDS: responses and side effects revisited.
    Tiu RV; Sekeres MA
    Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
    [No Abstract]   [Full Text] [Related]  

  • 34. The thalidomide saga.
    Melchert M; List A
    Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide.
    Weisel K; Kanz L
    Recent Results Cancer Res; 2014; 201():347-57. PubMed ID: 24756803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
    Kuendgen A
    Leuk Res; 2014 Mar; 38(3):287-8. PubMed ID: 24433864
    [No Abstract]   [Full Text] [Related]  

  • 39. Lenalidomide in multiple myeloma: Current status and future potential.
    Quach H; Kalff A; Spencer A
    Am J Hematol; 2012 Dec; 87(12):1089-95. PubMed ID: 22641420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
    Eclache V; Da Rocha A; Le Roux G; Fenaux P
    Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.